secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001104659-25-064145
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Phase 1b for GT-02287 enrolls 16 patients; biomarker data now expected Q4 2025
--------------------------------------------------------------------------------

- Enrollment reached 16 participants (target 15-20) despite 2-month protocol delay.
- Independent DMC recommends continue study unchanged; no serious adverse events reported.
- Faster enrollment means 90-day visit and CSF biomarker results earlier in Q4 2025 vs. Q1 2026.
- Screening window extended through July 31, 2025; planning to request dosing extension beyond 90 days in Australia.
- Long-term toxicology studies near completion; update on dosing extension expected before end of Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925064145/0001104659-25-064145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925064145/tm2518735d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-064145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer